Evidence map›Paper›PMID 36337063›Full record

ReviewIranian journal of biotechnology2022

The Gene Manipulation and Cellular Immunotherapy Combination in the Treatment of Cancer.

Fatemeh Khatami, Zahra Sadat Aghamir, Fatemeh Jahanshahi, Seyed Ariana Feiz-Abadi, Fatemeh Birang, Mahdi Khoshchehreh, Alireza Namazi Shabestari, Seyed Mohammad Kazem Aghamir

Open access · greenAbstract readReview
In one paragraph

Review in Iranian journal of biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Fatemeh KhatamiUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Zahra Sadat AghamirFaculty of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh JahanshahiIran University of Medical Sciences, Tehran, Iran.
Seyed Ariana Feiz-AbadiUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh BirangDepartment of Medical Laboratory Sciences, Allied Medical Faculty, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi KhoshchehrehDepartment of Pathology, University of California, Los Angeles, USA.
Alireza Namazi ShabestariDepartment of Geriatric Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Mohammad Kazem AghamirUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: The immune system is directly linked to the tumors, from tumor formation to the tumor's development and metastasis. So, the interest of scientists over the protective immunological mechanisms has increased and shown gifted strategy in cancer treatment. Evidence acquisition: Genetic engineering and cellular immunotherapy are two different advanced molecular mechanisms to modify the immune responses and genome. Gene manipulation is the bioengineering technology that allows vectors to transfer new genetic information into the target cells. Cellular immunotherapy is an excellent strategy that connects the body's immune system to fight cancer. Results & Conclusions: This review described that combination of genetic engineering and cellular immunotherapy has brought the novel antitumor repressive molecules stopping the tumor tissue immune tolerance and significantly expanding cancer therapy's effectiveness. Usually, cell immunotherapy and genetic engineering are considered two independent processes, and, in this review, we believe them in combinations. Here, we review these two novel approaches, and they are both combinations in terms of technological advances and clinical experience.

Indexed as

Chimeric Antigen Receptor T cellEngineered T cell receptorNatural Killer cellTumor-Infiltrating Lymphocyte

Identifiers

PMID36337063
PMCPMC9583824
OpenAlexW4308548606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.